Active surveillance of adverse events following childhood immunization in Singapore

Vaccine

Volumn 32, Issue 39, 2014, Pages 5000-5005

  Thoon, Koh Cheng ^a,b,c   Soh, Sally Bee Leng ^d   Liew, Woei Kang ^a   Gunachandran, Arunan ^a   Tan, Natalie Woon Hui ^a,b,c   Chong, Chia Yin ^a,b,c   Yung, Chee Fu ^e  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d HEALTH SCIENCES AUTHORITY   (Singapore)

^e TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Adverse events following immunization; Children; Singapore; Vaccines

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; FEBRILE CONVULSION; FEMALE; FOLLOW UP; HEPATITIS B; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INFANT; LONG TERM CARE; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; SINGAPORE; SYMPTOM; VACCINATION; VACCINE FAILURE; VERTICAL TRANSMISSION; ADVERSE EFFECTS; CHEMICALLY INDUCED; HEALTH SURVEY; PROCEDURES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BCG VACCINE; CAUSALITY; FEMALE; HUMANS; INFANT; LYMPHADENITIS; MALE; POPULATION SURVEILLANCE; SINGAPORE; VACCINATION;

EID: 84906089751     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.020     Document Type: Article

References (18)

1. World Health Organization, UNICEF, World Bank State of the world's vaccines and immunization 2009, World Health Organization, Geneva. 3rd ed.
2. Duclos P. A global perspective on vaccine safety. Vaccine 2004, 2001:2059-2063.
3. World Health Organization WHO/Europe launches plan for accelerated action to eliminate measles and rubella 2013, WHO Regional Office for Europe, Available from http://www.euro.who.int/en/health-topics/communicable-diseases/measles-and-rubella/news/news/2013/09/whoeurope-launches-plan-for-accelerated-action-to-eliminate-measles-and-rubella (accessed November 11, 2013) (updated September 18, 2013).
4. Health Science Authority HSA's role in the regulation of Western medicines in Singapore 2012, Singapore Government, Singapore, Available from http://www.hsa.gov.sg/publish/hsaportal/en/for_public/about_our_work/hsa_s_role_in_the.html (accessed April 17, 2013) (updated January 4, 2012).
5. World Health Organization Strategic Advisory Group of Experts on Immunization-report of the extraordinary meeting on the influenza A(H1N1) 2009 pandemic, 7 July 2009. Wkly. Epidemiol. Rec. 2009, 84:301-308.
6. Scheifele D.W., Halperin S.A., Members of the CPS/Health Canada, Immunization Monitoring Program, Active (IMPACT) Immunization monitoring program, active: a model of active surveillance of vaccine safety. Sem Pediatr Infect Dis 2003, 14:213-219.
7. Singapore Department of Statistics Population trends 2013, Singapore Government, Singapore, Available from http://www.singstat.gov.sg/publications/publications_and_papers/population_and_population_structure/population_trend.html (accessed April 22, 2014) (updated March 11, 2014).
8. Ministry of Health Singapore Hospital admission rates by age and sex 2012, Singapore Government, Singapore, Available from http://www.moh.gov.sg/content/moh_web/home/statistics/healthcare_institutionstatistics/hospital_admissionratesbyageandsex/Hospital_Admission_Rates_by_Age_and_Sex_20111.html (accessed 31 March, 2014) (updated 14 Jan 2014).
9. Singapore Economic Development Board and Ministry of Manpower Contact Singapore, Healthcare in Singapore 2013, Available from http://www.contactsingapore.sg/investors_business_owners/why_singapore/living/healthcare (accessed April 17, 2013).
10. Health Promotion Board National immunisation registry 2007, Singapore Government, Singapore, Available from http://www.nir.hpb.gov.sg/nir/sv/eservices/eservicesv?ACTION=DISPLAY_ABOUTUS (accessed April 17, 2013) (updated August 11, 2007).
11. Uppsala Monitoring Centre WHO-UMC causality assessment 2013, Available from http://who-umc.org/Graphics/24734.pdf (accessed April 22, 2013).
12. Dean A.G., Sullivan K.M., Soe M.M. Open source epidemiologic statistics for public health, version 3.0.1 2013, OpenEpi, Available from http://www.OpenEpi.com (accessed August 5, 2013) (updated April 6, 2013).
13. Health Science Authority Reports of lymphadenitis following administration of BCG Vaccine SSI® 2011, 13:31-32. HSA Adverse Drug Reaction News.
14. Milstien J.B., Gibson J.J. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Org 1990, 68:93-108.
15. Bonhoeffer J., Bentsi-Enchill A., Chen R.T., Fisher M.C., Gold M.S., Hartman K., et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009, 27:2289-2297.
16. Bonhoeffer J., Black S., Izurieta H., Zuber P., Sturkenboom M. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals 2012, 40(5):393-397.
17. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub R., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med. Care 2007, 45(10 suppl 2):S89-S95.
18. World Health Organization Causality assessment of an adverse event following immunization (AEFI). User manual for the revised WHO AEFI causality assessment classification 2013, World Health Organization, Available from http://www.who.int/vaccine_safety/publications/aevi_manual.pdf?ua=1 (accessed 5 June 2014).